Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
23 hedge funds and large institutions have $76.2M invested in Calliditas Therapeutics AB American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14.9M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$11.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.91M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$6.93M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.94M |
Top Sellers
CALT Hedge Fund Activity: Q2 2020 in Review
23 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q2 2020, worth a combined $76.2M.
Buyers outnumbered sellers: 23 funds opened new CALT positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $14.9M.
- 23 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $76.2M of Calliditas Therapeutics AB American Depositary Shares stock for Q2 2020.
- 23 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q2 2020 and 0 closed out, a net change of +23 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q2 2020 was BVF Inc, an estimated $14.9M added.
Based on aggregated 13F filings for Q2 2020.